

PTO/SB/08b (04-09)

Approved for use through 05/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/665,522-Conf. #5813	
			Filing Date	September 22, 2003	
			First Named Inventor	Andre Stamm	
			Art Unit	1615	
			Examiner Name	H. N. Sheikh	
Sheet	1	of	1	Attorney Docket Number	31672-224622

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-4,925,672	05-15-1990	Gremm et al.	
	AB*	US-5,385,739	01-31-1995	Debregeas et al.	
	AC*	US-6,074,670	06-13-2000	Stamm et al.	
	AD*	US-6,444,225	09-03-2002	Sherman	
	AE*	US-7,276,249	10-02-2007	Ryde et al.	
	AF*	US-7,320,802	01-22-2008	Ryde et al.	
	AG*	US-6,375,986	04-23-2002	Ryde et al.	
	AH*	US-6,277,405	08-21-2001	Stamm et al.	
	AI*	US-7,037,529	05-02-2006	Stamm et al.	
	AJ*	US-7,041,319	05-09-2006	Stamm et al.	
	AK*	US-6,652,881	11-25-2003	Stamm et al.	
	AL*	US-6,589,552	07-08-2003	Stamm et al.	
	AM*	US-5,952,396	09-14-1999	Chang	
	AN*	US-6,027,747	02-22-2000	Terracol et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	BA	FR-2758459	07-24-1998	Pharma Pass	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	CA	SHEU et al., International Journal of Pharmaceuticals, pp. 137-146, March 15, 1994.			
	CB	Opposition to Israel Patent No. 130790 filed 05-04-2005 by Teva; and Remarks in Response to Opposition filed on 09-23-2005 (English Language Translation)			

Examiner Signature	/Humera Sheikh/	Date Considered	08/12/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.